Cancer

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the…

12 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the…

12 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

12 months ago

H1 Welcomes Former FDA Commissioner to Board of Directors, Acquires Ribbon Health, and Unveils 2025 Product Roadmap

Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,…

12 months ago

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical…

12 months ago

Transcarent To Acquire Accolade

Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment…

12 months ago

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the…

12 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory…

12 months ago

SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:…

12 months ago

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive…

12 months ago